Presenting Research at ACG 2018 on Quality of Life of Patients with Clostridium difficile

22 August 2018

The Da Volterra team is thrilled to present a poster at the next conference of the American College of Gastroenterology that will take place in Philadelphia, PA, USA on Oct 5 -10.

The poster will be entitled “Perception of Quality of Life Among People Experiencing or Having Experienced a Clostridium difficile Infection in the United States: Qualitative Review of Respondents Verbatim” and will present the key results of a quality of life survey conducted among 350 US patients with C.difficile infection.

Of note, the poster has been granted two awards by the American College of Gastroenterology: the Presidential Poster Award and the Category Award marking the poster as one of the best in the “Colon” category. Our team is thrilled by this acknowledgment and looks forward to the conference to share all the details of our research with the medical and patient community.

The abstract of the poster is shared below.

 

P1877 - Perception of Quality of Life Among People Experiencing or Having Experienced a Clostridium difficile Infection in the United States: Qualitative Review of Respondents Verbatim

Tuesday, October 9, 10:30 AM – 4:00 PM

Category: Colon

Lise Lurienne, PharmD, MSc1, Pierre-Alain Bandinelli1, Thibaut Galvain, PharmD, MSc1, Charles-Alexis Coursel1, Philippe Boutier1, Caterina Oneto, MD2, Paul Feuerstadt, MD, FACG3

1Da Volterra, Paris, Ile-de-France, France; 2Concorde Medical Group, New York, NY; 3Yale University School of Medicine / Gastroenterology Center of Connecticut, Westport, CT

Award: Category Award (Colon)

Award: Presidential Poster Award

 

Introduction: Although the incidence, severity and mortality of Clostridium difficile infections (CDI) have been increasing, patients’ quality of life changes resulting from CDI have not been studied thoroughly. This study aimed at exploring the physical, psychological, social and financial consequences of CDI for patients during and after the disease.

Methods: An observational, cross-sectional study involving 350 subjects with a self-reported diagnosis of CDI was conducted through an online self-administered survey. Most questions comprised non-compulsory comment fields which were studied qualitatively to identify 32 consequences of CDI categorized in 5 groups (symptomatic, psychological, relational, adaptation, productivity). Patients were grouped into those who had active disease at the time of the survey, “Current CDI” and those who had a history of CDI, “Past CDI”.

Results: 115 subjects (33%) reported Current CDI and 235 (67%) reported Past CDI. A majority of Current CDI subjects (86%) spontaneously reported at least one of the symptomatic factors, primarily physical pain (55%) and fatigue (51%). These symptoms remained present frequently after the infection (72%), with physical pain and fatigue being mentioned by approximately one third of respondents in the Past CDI cohort (33% and 31%). The percent of subjects reporting without prompting at least one psychological item remained high during and after CDI (58% and 70%, respectively, p=0.053). Two consequences were seen more frequently in the Past CDI cohort: Post-Traumatic Stress Disorder (11% vs. 0%, p<0.001) and fear of recurrence (46% vs.15%, p<0.001) including the fear of taking antimicrobials again (25% vs. 5%, p<0.001). Life-style adaptation measures seemed to decrease after clearance of the infection but were high in both cohorts (77% vs. 60%, p<0.001); many patients reported changes in their eating habits during and after CDI (29% and 41%, respectively). Finally, 16% of Current CDI and 11% of Past CDI respondents mentioned a major impact of CDI on their professional life (e.g. lost job, forced retirement or inability to work) (p=0.296).

Discussion: While the societal burden of CDI is well described in the literature, our study is one of the first aimed at understanding the major burden of CDI on patients’ quality of life. Our results highlight the long-lasting nature of CDI and further reinforce the need for enhanced therapeutics in the prevention and treatment of this devastating infection.